During Andrew Witty’s final full year at GSK, vaccines outgrew each of GSK’s other units.

In spite of trouble picking up steam with its first-of-a-kind dengue shot, Sanofi’s vaccines unit chipped in with 8.8% growth on the year.

Gardasil could see some trouble in the U.S. this year, Merck is advising.

A Zika vaccine safe enough for women of childbearing age may still not be available before 2020, the World Health Organization estimated.

A new survey documents strong support by Americans that the benefits of childhood immunizations outweigh any potential risks.

Brazil’s health authority will expand its yellow fever vaccine stockpile by 11.5 million doses as an outbreak rages in the country. Previous outbreaks in…

Having won FDA approval in May 2015, Sanofi Pasteur’s DTaP-IPV vaccine Quadracel is now available in the U.S. and ready to challenge GlaxoSmithKline’s Kinrix.

Pfizer’s blockbuster pneumococcal vaccine Prevnar stumbled in fourth-quarter results released Tuesday, falling far short of Street estimates and dragging on…

Sanofi's vaccines unit has settled a class-action suit that claimed the company leveraged its heavyweight status in the field to knock back a rival…